Triamcinolone Acetonide

In the clinical treatment of allergic and autoimmune inflammatory diseases, glucocorticoid drugs have always been one of the core medication options. As a long-acting adrenocortical hormone drug, triamcinolone acetonide exerts potent anti-inflammatory, anti-allergic and immunosuppressive effects by inhibiting the aggregation of inflammatory cells, reducing the release of inflammatory mediators and lowering capillary permeability. It is widely used clinically in the treatment of skin diseases such as neurodermatitis, eczema and psoriasis, as well as bronchial asthma, rheumatoid arthritis, synovitis, connective tissue diseases, etc. It can also be injected into the joint cavity to relieve local inflammatory pain. Its applicable population covers adults and pediatric patients who meet the indications, and it is a common basic drug for chronic disease inflammation management.

According to public industry data, the overall domestic market size of glucocorticoid APIs exceeded 4.5 billion yuan in 2023, among which the annual compound growth rate of triamcinolone acetonide remains at around 6%, with stable downstream demand that continues to grow driven by the increase in the number of visits to dermatology and rheumatology and immunology departments. At present, the domestic production of triamcinolone acetonide APIs is dominated by local enterprises, with a relatively high market concentration. The top 3 enterprises account for nearly 80% of the domestic supply share, most of which have passed FDA and CEP certifications, and their products are also supplied to overseas high-end markets. This variety has been included in multiple batches of national centralized procurement, and the price of the selected preparations has dropped by more than 60%, further driving the demand for upstream API volume release.

The original research enterprise of triamcinolone acetonide is Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, and the original research brand name is "Kenacort-A". Its core compound patent expired globally in 1985. The original research dosage forms marketed in China mainly include injections (1ml:40mg), ointments (10g:2.5mg) and nasal sprays. Among them, triamcinolone acetonide injectable suspension and triamcinolone acetonide ointment have been included in the *Catalogue of Reference Preparations for Chemical Drugs* issued by the National Medical Products Administration. More than 20 domestic enterprises have obtained approval for marketing their preparation products. Data from the CDE API Registration Platform shows that there are currently 11 registration numbers for triamcinolone acetonide APIs, 8 of which are in status A and can be supplied to domestic preparation manufacturers. (Data as of October 2024, please refer to the official CDE website for the latest information)

CATO can provide a full set of impurity reference standards for triamcinolone acetonide API. All products meet the compliance requirements of multiple regulations such as Chinese Pharmacopoeia and FDA. Most products are regularly in stock, and spot orders submitted before 16:00 can be shipped on the same day, which can efficiently meet the reference standard use needs of pharmaceutical enterprises in the process of R&D, quality research and production.